151 related articles for article (PubMed ID: 10663642)
1. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
Cancer Chemother Pharmacol; 2000; 45(3):239-46. PubMed ID: 10663642
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
4. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Strumberg D; Harstrick A; Doll K; Hoffmann B; Seeber S
Anticancer Drugs; 1996 Jun; 7(4):415-21. PubMed ID: 8826610
[TBL] [Abstract][Full Text] [Related]
6. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.
Nath K; Nelson DS; Putt ME; Leeper DB; Garman B; Nathanson KL; Glickson JD
PLoS One; 2016; 11(6):e0157125. PubMed ID: 27285585
[TBL] [Abstract][Full Text] [Related]
8. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells.
Letourneau S; Greenbaum M; Cournoyer D
Hum Gene Ther; 1996 May; 7(7):831-40. PubMed ID: 8860835
[TBL] [Abstract][Full Text] [Related]
11. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
Yagi MJ; Chin SE; Scanlon KJ; Holland JF; Bekesi JG
Biochem Pharmacol; 1985 Jul; 34(13):2347-54. PubMed ID: 4040366
[TBL] [Abstract][Full Text] [Related]
12. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
13. Alkylating agent resistance: in vitro studies with human cell lines.
Frei E; Cucchi CA; Rosowsky A; Tantravahi R; Bernal S; Ervin TJ; Ruprecht RM; Haseltine WA
Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2158-62. PubMed ID: 3856890
[TBL] [Abstract][Full Text] [Related]
14. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.
Graham CH; Kobayashi H; Stankiewicz KS; Man S; Kapitain SJ; Kerbel RS
J Natl Cancer Inst; 1994 Jul; 86(13):975-82. PubMed ID: 8007019
[TBL] [Abstract][Full Text] [Related]
15. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
16. Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.
Ford JM; Hait WN; Matlin SA; Benz CC
Cancer Lett; 1991 Jan; 56(1):85-94. PubMed ID: 2004358
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
18. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
19. Patterns of resistance and therapeutic synergism among alkylating agents.
Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
[TBL] [Abstract][Full Text] [Related]
20. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.
Frei E; Richardson P; Avigan D; Bunnell C; Wheeler C; Elias A
Bone Marrow Transplant; 1999 Nov; 24(9):939-45. PubMed ID: 10556951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
